Which company received FDA approval in 2022 for a gene therapy to treat a rare g

Practice Questions

Q1
Which company received FDA approval in 2022 for a gene therapy to treat a rare genetic disorder?
  1. Novartis
  2. Bluebird Bio
  3. CRISPR Therapeutics
  4. Sangamo Therapeutics

Questions & Step-by-Step Solutions

Which company received FDA approval in 2022 for a gene therapy to treat a rare genetic disorder?
  • Step 1: Identify the year 2022.
  • Step 2: Look for companies that received FDA approval in 2022.
  • Step 3: Find out which company received approval for a gene therapy.
  • Step 4: Confirm that Bluebird Bio is the company that received FDA approval.
  • Step 5: Check the name of the gene therapy approved by Bluebird Bio.
  • Step 6: Verify that the gene therapy is called Zynteglo.
  • Step 7: Understand that Zynteglo is used to treat beta-thalassemia, which is a rare genetic blood disorder.
No concepts available.
Soulshift Feedback ×

On a scale of 0–10, how likely are you to recommend The Soulshift Academy?

Not likely Very likely